REGENXBIO Inc. (NASDAQ:RGNX) Shares Purchased by Sigma Planning Corp

Sigma Planning Corp raised its stake in REGENXBIO Inc. (NASDAQ:RGNX) by 17.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 38,210 shares of the biotechnology company’s stock after buying an additional 5,701 shares during the quarter. Sigma Planning Corp owned about 0.08% of REGENXBIO worth $401,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Redmile Group LLC raised its stake in shares of REGENXBIO by 21.0% in the 1st quarter. Redmile Group LLC now owns 4,551,556 shares of the biotechnology company’s stock valued at $95,901,000 after acquiring an additional 790,866 shares during the period. Assenagon Asset Management S.A. raised its position in REGENXBIO by 258.7% in the second quarter. Assenagon Asset Management S.A. now owns 816,384 shares of the biotechnology company’s stock valued at $9,552,000 after purchasing an additional 588,773 shares during the period. Vanguard Group Inc. lifted its stake in REGENXBIO by 9.8% during the first quarter. Vanguard Group Inc. now owns 4,876,881 shares of the biotechnology company’s stock worth $102,756,000 after purchasing an additional 436,043 shares in the last quarter. Artal Group S.A. purchased a new position in shares of REGENXBIO during the first quarter worth $5,268,000. Finally, Integral Health Asset Management LLC grew its stake in shares of REGENXBIO by 25.0% in the second quarter. Integral Health Asset Management LLC now owns 950,000 shares of the biotechnology company’s stock valued at $11,115,000 after buying an additional 190,000 shares in the last quarter. Hedge funds and other institutional investors own 88.08% of the company’s stock.

REGENXBIO Trading Down 13.6 %

Shares of RGNX stock opened at $9.63 on Friday. The company has a market cap of $477.07 million, a P/E ratio of -1.91 and a beta of 1.23. The firm has a fifty day moving average price of $10.50 and a 200 day moving average price of $12.31. REGENXBIO Inc. has a 12 month low of $8.53 and a 12 month high of $28.80.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on RGNX. Morgan Stanley reissued an “overweight” rating and set a $22.00 target price on shares of REGENXBIO in a research note on Friday. HC Wainwright raised their price objective on shares of REGENXBIO from $39.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Chardan Capital restated a “buy” rating and issued a $52.00 price objective on shares of REGENXBIO in a report on Tuesday, October 22nd. StockNews.com upgraded shares of REGENXBIO from a “sell” rating to a “hold” rating in a report on Friday, September 20th. Finally, Barclays dropped their price target on shares of REGENXBIO from $55.00 to $50.00 and set an “overweight” rating for the company in a research note on Monday, August 5th. Two analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat.com, REGENXBIO presently has a consensus rating of “Moderate Buy” and an average target price of $35.64.

Insiders Place Their Bets

In other REGENXBIO news, Director Argeris N. Karabelas sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $10.11, for a total transaction of $101,100.00. Following the sale, the director now owns 11,286 shares of the company’s stock, valued at approximately $114,101.46. This trade represents a 46.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 13.13% of the stock is owned by company insiders.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.